New hope for tough myeloma: phase 3 trial of IBI3003 launches
NCT ID NCT07623798
First seen Jun 14, 2026 · Last updated Jun 14, 2026
Summary
This study tests a new drug called IBI3003 in 255 adults with multiple myeloma that has returned or not responded to prior treatments. Participants will receive either IBI3003 or one of two standard treatment combinations chosen by their doctor. The main goal is to see if IBI3003 helps people live longer without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ZhongShan Hospital FuDan University
Shanghai, Shanghai Municipality, 132101, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.